Nationwide registry study reveals improved survival with targeted and immunotherapy in metastatic mucosal melanoma, highlighting the utility of molecular profiling.
Mucosal melanomas are a rare melanoma subtype with poor prognosis. This project aimed to identify the main driver mutations of the different mucosal melanomas and to evaluate the efficacy of targeted/immunotherapies in patients with metastatic disease in current practice. In addition, the baseline clinicopathological characteristics, metastatic patterns, and primary treatment strategies and survival of mucosal melanoma subtypes were studied. The Dutch nationwide pathology databank (Palga) and the Netherlands Comprehensive Cancer Organisation (IKNL) were queried for all patients with a diagnosis of mucosal melanoma (1989-2021). The dataset included a total of 1481 patients. Mutation status was assessed in 397 patients and in 170 patients (43%) a driver mutation was discovered. Patients with metastatic disease who received targeted/immunotherapy did show a better survival. The liver and lung were the predominant locations of the first metastasis. The data in the present study implies that patients with metastatic disease mucosal melanoma might benefit from targeted/immunotherapies. Molecular analysis should be considered in these patients.
No takes yet. Share an insight, caveat, or question.
Jutten et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: